Reports
2008-06-06
Sveriges sammanlagda portfölj av läkemedelsprojekt avancerar mot marknaden, både i antal och i nya behandlingar. Samma antal bolag driver i år 32 fler läkemedelsprojekt; 142 stycken totalt, varav 76 i kliniska faser. Antal projekt i fas III har ökat. Projekten är väl spridda inom ett stort antal olika områden, medan en majoritet återfinns inom infektionssjukdomar . Aktiviteten i den svenska Lif...
2008-06-05
SwedenBIOs enkät till 100 VDar i den svenska Life Science industrin visar att över 90 procent av dem som svarade vill investera och växa sitt företag i Sverige, men endast 60 procent planerar att nyanställa inom det närmsta året. Samtidigt är bolagen attraktiva utomlands och konkurrensen om bolagens investeringar ökar. Närmre hälften av de som svarade har alla fått konkreta erbjudanden om att...
2008-02-16
Olle Stendahl presenterade sin utredning om den kliniska forskningen i Sverige den 15 februari 2008.
2008-02-05
Report developed by the Royal Institute of Technology, Karolinska Insitutet and the Karolinska Universtity Hospital
2008-02-01
SwedenBIO har lämnat sin forsknings- och innovationsstrategi inför forskningspolitiska propositionen 2008. Strategin har utarbetats av SwedenBIOs arbetsgrupper inom forskning och kliniska prövningar.
2007-02-28
This reportproposes government measures on how the Swedish financing environment for innovations can be strengthened. The report will be an important tool in SwedenBIOs fact-based dialogue with government and decision makers.
2006-04-21
The Government held Industry sector discussions ('Branschsamtal') with the biotech industry during 2005. This document is a summary of the discussions and the Government actions and strategies for the future.
2006-06-21
This report is a benchmark of different investor incentives available in Canada, Ireland, United Kingdom, Denmark and Singapore. The results are used as a basis for suggestions on how to further develop the financial environment in Sweden to build successful and vibrant Life Science clusters with sustainable growth potential in Sweden.
2006-06-09
Small, research-intensive companies often face a difficult financial situation in the early stages. Revenues might be several years away, though they can indeed be significant when a a new invention is finally brought to market. Several countries has recognized this problem and have implemented tax incentives to stimulate the growth of these small companies. This report is a four-country...
2006-04-25
This report is an investigation of the drug pipeline of the Swedish Biotech Industry as of February 2006. Projects in clinical trials or in late pre-clinical phase (within 12 months from entering) are covered. The report was compiled by SwedenBIO and financed and supported by ISA, Invest in Sweden Agency and VINNOVA.
2005-10-05
SwedenBIO has assessed the financial climate facing Swedish biotech and medtech companies and their investors through a questionnaire-based survey. Compared to last years, the responses indicate a positive trend towards an easier funding situation. Seed and early stage financing is still a bottleneck, however, and the companies call for measures to lower the risk of investing in high-risk...
2004-07-01
A four-country-comparison of incentives for biotech growth in Europe has been performed. Countries used in the study are Denmark, France, Finland and Ireland. All four countries showed many common denominators regarding governmental leadership, such as creation of incubators, allocating funds, supportive instruments for collaboration between research institutions and the industry.
2005-08-19
Experts claim that the global biotech industry is going to expand strongly during the next years. How will Sweden be able to compete with other countries for jobs and investments? SwedenBIO in collaboration with the trade unions arranged a seminar in Visby during Almedalsveckan, focusing on how to meet the challenge. Key note speakers included Jan Lundberg, AstraZeneca, Harriet Wallberg-Henriks...